{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-029741","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2021-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.168109+00:00","generated_at":"2026-06-28T05:38:28.020401+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients","bullets":["Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.","End-of-treatment mortality: 4.5% OT-101 vs 20% placebo.","Viral load knockdown >96% in 89% of OT-101 patients vs 67% placebo.","Overall survival for critical patients: 14 days OT-101 vs 4 days placebo (p<0.0166)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-029741","json":"https://secwatch.observer/filing/0001493152-21-029741.json","markdown":"https://secwatch.observer/filing/0001493152-21-029741.md","text":"https://secwatch.observer/filing/0001493152-21-029741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315221029741/0001493152-21-029741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315221029741/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:38:28.020401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}